Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Diabetic Macular Edema (LUDIC)
NCT01315275Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2011
- Primary completion
- Aug 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Primary endpoint: Proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA) at 6 months. Started Feb 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01315275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01315275.